Clinical Trials
5 trialsNCT04940052 2026-06-04
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
Novartis
Phase 3 Active not recruiting
NCT02152995 2026-04-13
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01723202 2025-08-24
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT01553851 2016-12-26
GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
Washington University School of Medicine
Phase 2 Completed